TITLE:
First in Man Topical Treatment of Melanoma with Solasodine Glycosides in a Formulation Curaderm: A Case Report
AUTHORS:
B. E. Cham
KEYWORDS:
Melanoma, Curaderm, BEC, Solamargine, Non-Melanoma Skin Cancer, Metastasis
JOURNAL NAME:
Journal of Cancer Therapy,
Vol.11 No.10,
October
22,
2020
ABSTRACT: Background: There is ample evidence to support the safety and
efficacy of the topical anticancer cream Curaderm in the treatment of
non-melanoma skin cancers. Curaderm contains the natural glycoalkaloid
solamargine in the form of BEC, which has been established as a novel
antineoplastic agent. BEC is the initials of the inventor of the described
technology. It is known that BEC expresses anti-melanoma properties in cell
culture and animals. Because of potential metastasis, clinical work with BEC on
melanoma was stalled. However, recent studies show that BEC has anti-metastatic
properties and this, together with currently better understanding of the mode
of anti-cancer actions of BEC, has led to the treatment of a patient who refused
to have surgery for her clinically diagnosed stage II melanoma. Treatment: A
67-year woman had a birthmark that developed into a clinically diagnosed stage
II melanoma and was treated with topical application of Curaderm twice daily
for 7 weeks. Results: The pattern of response of the melanoma to
Curaderm therapy was similar to that observed when basal cell carcinoma is
treated with Curaderm. The melanoma responded rapidly to the treatment and in 7
weeks the lesion was removed with no demonstrable side effects. The cosmetic
end result was very acceptable. Conclusion: The clinical resolution of
the melanoma with Curaderm pharmacotherapy conforms to the cell culture and
animal observations that solasodine rhamnosides, and thus Curaderm, is very
specific and efficacious for the first in man treatment of melanoma, creating
the possibility of a simple treatment for melanoma. Further investigations with
controlled clinical trials are warranted.